Triple negative breast cancer–prognostic role of immune-related factors: a systematic review
ES Stovgaard, D Nielsen, E Hogdall, E Balslev - Acta Oncologica, 2018 - Taylor & Francis
Purpose: Treatment of breast cancer has been increasingly successful in recent years with
the advent of HER2-receptor targeted treatment and endocrine treatment. However, the …
the advent of HER2-receptor targeted treatment and endocrine treatment. However, the …
ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells
J Faget, N Bendriss-Vermare, M Gobert, I Durand… - Cancer research, 2012 - AACR
Human breast tumors are infiltrated by memory CD4+ T cells along with increased numbers
of regulatory T cells (Treg) and plasmacytoid dendritic cells (pDC) that facilitate immune …
of regulatory T cells (Treg) and plasmacytoid dendritic cells (pDC) that facilitate immune …
Plasmacytoid dendritic cells recruited by HIF-1α/eADO/ADORA1 signaling induce immunosuppression in hepatocellular carcinoma
L Pang, KTP Ng, J Liu, WHO Yeung, J Zhu, TLS Chiu… - Cancer Letters, 2021 - Elsevier
Plasmacytoid dendritic cells (pDCs) play immunosuppressive roles in the tumor
microenvironment (TME). However, the molecular mechanisms underlying the recruitment …
microenvironment (TME). However, the molecular mechanisms underlying the recruitment …
[HTML][HTML] Recruitment and expansion of tregs cells in the tumor environment—how to target them?
J Cinier, M Hubert, L Besson, A Di Roio, C Rodriguez… - Cancers, 2021 - mdpi.com
Simple Summary The immune response against cancer is generated by effector T cells,
among them cytotoxic CD8+ T cells that destroy cancer cells and helper CD4+ T cells that …
among them cytotoxic CD8+ T cells that destroy cancer cells and helper CD4+ T cells that …
[HTML][HTML] STAT3 interactors as potential therapeutic targets for cancer treatment
F Laudisi, F Cherubini, G Monteleone… - International journal of …, 2018 - mdpi.com
Signal transducers and activators of transcription (STATs) mediate essential signaling
pathways in different biological processes, including immune responses, hematopoiesis …
pathways in different biological processes, including immune responses, hematopoiesis …
[HTML][HTML] Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer
Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer
patients, in particular in estrogen receptor negative (ER−) cancers, by reducing rates of …
patients, in particular in estrogen receptor negative (ER−) cancers, by reducing rates of …
[HTML][HTML] Type I interferon production of plasmacytoid dendritic cells under control
D Bencze, T Fekete, K Pázmándi - International journal of molecular …, 2021 - mdpi.com
One of the most powerful and multifaceted cytokines produced by immune cells are type I
interferons (IFNs), the basal secretion of which contributes to the maintenance of immune …
interferons (IFNs), the basal secretion of which contributes to the maintenance of immune …
[HTML][HTML] Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer
Y Lin, X Jing, Z Chen, X Pan, D Xu, X Yu, F Zhong… - Theranostics, 2023 - ncbi.nlm.nih.gov
Background: Studies have shown that the expression of histone deacetylases (HDACs) is
significantly related to the tumor microenvironment (TME) in gastric cancer. However, the …
significantly related to the tumor microenvironment (TME) in gastric cancer. However, the …
Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL
Even though melanoma is considered to be one of the most immunogenic solid tumors,
handling its development remains a challenge. The basis for such escape from antitumor …
handling its development remains a challenge. The basis for such escape from antitumor …
[HTML][HTML] A characterization of dendritic cells and their role in immunotherapy in glioblastoma: from preclinical studies to clinical trials
S Srivastava, C Jackson, T Kim, J Choi, M Lim - Cancers, 2019 - mdpi.com
Glioblastoma (GBM) is the most common and fatal primary central nervous system
malignancy in adults with a median survival of less than 15 months. Surgery, radiation, and …
malignancy in adults with a median survival of less than 15 months. Surgery, radiation, and …